clinical trial · NCT07264426
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
argenx·—·recruiting·n = 200
Chronic Inflammatory Demyelinating PolyradiculoneuropathyCIDPCIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)Efgartigimod PH20 SC
brief summary
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
started
Aug 11, 2025
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Apr 23, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol